Updated on 20 May 2015
Caldera Health, prostate cancer diagnostics company has appointed Dr Keith Hudson as director of Research and Development (R&D).
In 1993, Dr Husdon has been a PhD holder in immunology, University of Auckland and has spent conducting almost five years in the University of Oxford and then in the University of Birmingham. In 1998, he returned to New Zealand and has worked for Genesis Research and Development, leaded a research program which has resulted in several patent applications and has received government funding for about NZ $6 million.
Dr Hudson worked as chief scientific officer in Cartesian Group. He was also active in developing bioinformatics software that had turned genomic DNA information into useable gene sequences by using a patented pattern search technology.
Most recently he has worked for academic publishing company, Adis-Springer (an Australasian subsidiary of the global scientific, technical and medical publishing giant, Springer) as chief editor of "Molecular Diagnosis and Therapy" and "BioDrugs".
Over the years in his career, Dr Hudson has been awarded three patents and another patent application is in progress, and has received over $7 million in government finding. He has written chapters in four books and authored 18 refereed publications in scientific journals.
"We are very much delighted to have appointed a person like Dr Husdon to lead our scientific, bioinformatics and clinical programs, and ready our products for commercialization," said Mr Alastair MacCormick, Chairman of Caldera Health. He continued, "Dr Husdon is an experienced researcher with excellent credentials, has proven leadership capability and a sound commercial background."
According to Mr Jim Watson, Caldera's scientific advisor, Dr Husdon is a gifted New Zealand scientist who has enjoyed an outstanding international career in science and has considerable business experience of startup biotech companies. He is an excellent choice to lead the next phase of Caldera's R&D program.